Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People whose ability to carry out daily activities is rated at a functional level of 0, 1, or 2 on a standard cancer performance scale (where 0 means fully active and 2 means capable of self-care but unable to work)
• People with a confirmed diagnosis of certain blood cancers expected to carry a protein called CD20 on their cancer cells, including specific types of lymphoma (follicular lymphoma grades 1–3a, or diffuse large B-cell lymphoma/transformed follicular lymphoma), who have already tried at least one or two previous treatments depending on which part of the trial they are joining
• People with diffuse large B-cell lymphoma or transformed follicular lymphoma who have had only one prior treatment and are not considered suitable for a stem cell transplant using their own cells, or who are not able to receive a specialised cell therapy called CAR-T, for reasons defined by the trial
• People whose lymphoma shows up as active on a PET scan (a type of imaging scan that detects cancer activity)
• People who have at least one measurable area of lymphoma visible on a CT or PET/CT scan
• People who can provide a tumour tissue sample (biopsy) and its associated pathology report for diagnosis confirmation
• People who have adequate blood count levels without needing growth factor support or blood transfusions in the 14 days before starting the trial
• People with normal blood test results as required by the trial
• Women of childbearing potential who agree to use contraception or remain abstinent for specified time periods after treatment ends (the required duration depends on which study drugs are received)
• Men who agree to use a condom, remain abstinent, and not donate sperm for specified time periods after treatment ends (the required duration depends on which study drugs are received)

Who may not be able to join:

• People who are pregnant, breastfeeding, or planning to become pregnant during the study or within specified periods after the last dose of study treatment
• People who have received certain immune-modulating drugs (such as lenalidomide, pomalidomide, or similar medicines) within 4 weeks before starting the relevant study drugs
• People who are unable to swallow tablets, or who have ongoing moderate-to-severe diarrhoea or absorption problems that cannot be managed with medication
• People with a specific heart rhythm measurement (QTc interval) above 470 milliseconds on a heart trace (ECG)
• People who have previously received certain treatments, including the study drugs mosunetuzumab or glofitamab, other similar targeted antibody therapies, a donor stem cell transplant, or a solid organ transplant
• People who have received certain other treatments too recently before joining — including radiotherapy within the past 2 weeks, a stem cell transplant using their own cells within the past 100 days, CAR-T cell therapy within the past 30 days, certain antibody-based cancer treatments within the past 4 weeks, radioimmunotherapy within the past 12 weeks, immune-suppressing medications within the past 2 weeks, or other cancer treatments within the past 4 weeks or within 5 half-lives of the drug (whichever is shorter)
• People who have received a live vaccine within 4 weeks before starting the trial, or who are expected to need one during the trial or within 5 months after finishing treatment
• People with a current or past history of lymphoma that has spread to the brain or spinal fluid
• People with a history of severe allergic or anaphylactic reactions to antibody-based therapies
• People with a history of certain autoimmune conditions, including but not limited to lupus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, myositis, or other conditions where the immune system attacks the body
• People who have had major surgery or a serious injury within 28 days before joining the trial, or who are expected to need major surgery during the trial
• People who still have significant side effects from previous cancer treatments that have not improved to a mild level
• People with other serious ongoing health conditions (such as significant heart, lung, or liver disease, recent stroke, active infection, or others) that could interfere with the trial
• People joining the glofitamab part of the trial whose cancer did not respond to, or came back within 6 months of, a previous treatment containing a medicine called obinutuzumab

Important: Always verify eligibility with the trial site directly before applying.